Teriparatide is an anabolic agent used in the treatment of osteoporosis in adults, particularly in postmenopausal women and individuals at high risk of fractures. By stimulating bone formation and increasing bone mineral density, teriparatide helps strengthen bones and reduce the risk of fractures, especially in the spine and hip. This medication is particularly relevant for patients with glucocorticoid-induced osteoporosis and those with a history of fractures. In summary, teriparatide is a critical therapy for enhancing bone strength and preventing osteoporosis-related fractures.
Teriparatide acts as a parathyroid hormone analog, stimulating osteoblast activity and increasing calcium absorption in the intestines while decreasing renal calcium excretion, leading to enhanced bone formation.



